



## Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17

September 10, 2019

- Event to be held ahead of two Phase 2 topline data readouts of praliguat in diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF), anticipated in Q4 2019 –

CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will host a webcast investor event, to be held in New York City, on Tuesday, September 17, 2019 from 8:00 a.m. to 10:00 a.m. Eastern Time.



Learn more about praliguat ahead of its two Phase 2 data readouts anticipated in Q4 2019.



Learn more about praliguat ahead of its two Phase 2 data readouts anticipated in Q4 2019.

This first Cyclerion live investor event will focus on praliguat, the company's investigational, orally administered, once-daily systemic sGC stimulator designed for the treatment of serious cardiometabolic diseases. External subject matter experts – Dr. James Udelson of Tufts Medical Center and Dr. Barbara Gillespie of the University of North Carolina and Covance – and members of Cyclerion's leadership team will review the role of the nitric oxide/sGC system in cardiorenal physiology, the praliguat development program, and the ongoing Phase 2 clinical studies investigating praliguat as a potential treatment for diabetic nephropathy and for HFpEF. Both studies are fully enrolled, and topline clinical results are expected in Q4 2019.

Professional investors and equity research analysts are invited to attend the event in person. Please contact Jessi Rennekamp at [jrennekamp@cyclerion.com](mailto:jrennekamp@cyclerion.com) for additional information.

To join the live webcast, please visit the "[Investors and Media](#)" section of the Cyclerion website at [www.cyclerion.com](http://www.cyclerion.com) at least 15 minutes prior to the start of the event.

A webcast replay will be available on the Cyclerion website beginning approximately two hours after the event and will be archived for 21 days.

### About Cyclerion Therapeutics

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs include olinciguat in Phase 2 development for sickle cell disease, praliguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.

For more information about Cycleron, please visit <https://www.cycleron.com/> and follow us on Twitter ([@Cycleron](https://twitter.com/Cycleron)) and LinkedIn ([www.linkedin.com/company/cycleron](https://www.linkedin.com/company/cycleron)).

### **Forward Looking Statement**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements about the anticipated timing of release of data from our clinical trials. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those listed under the “Risk Factors” section and elsewhere in our Registration Statement on Form S-1 filed on April 18, 2019, with the Securities and Exchange Commission (SEC), and in subsequent reports that we file with the SEC. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and we undertake no obligation to update these forward-looking statements, except as required by law.

### **Investors**

Brian Cali, (857) 338-3262  
[bcali@cycleron.com](mailto:bcali@cycleron.com)

### **Media**

Jessi Rennekamp, (857) 338-3319  
[jrennekamp@cycleron.com](mailto:jrennekamp@cycleron.com)

A photo accompanying this announcement is available at <https://www.globenewswire.com/NewsRoom/AttachmentNg/06060dbc-ed8f-46e2-af45-bcead4cc40a8>



Source: Cycleron Therapeutics, Inc.